

Drug	Indication	Decision	Notes
Fluoxetine dispersible tablets (<i>Olena</i>)	Depression, bulimia nervosa and obsessive compulsive disorder	GREEN	New dispersible tablet formulation approved by PACEF as the preferable alternative to liquid formulations in most patients with swallowing difficulties.
Ropinirole sustained release tablets (<i>Repinex XL</i>)	Parkinson's disease	AMBER	New lower cost prolonged release formulation approved for use as an alternative to the premium cost brand Requip XL. This offers potential savings to practices and CCGs, but to realise saving it must be prescribed by brand.
Lecicarbon A suppositories	Constipation	RED-RED	A new suppository formulation not approved for use with Lincolnshire, because of the lack of comparative data and relatively high cost compared to alternative formulations.
Alprostadil 300mcg in 100mg cream (<i>Vitaros</i>).	Erectile Dysfunction	RED	New cream formulation of alprostadil providing a less invasive method of administration than other alprostadil formulations. Each dose of cream is provided in an <i>AccuDose</i> container which allow for administration directly into the urethra. Approved for use by ULHT Erection dysfunction clinics only, who will be auditing use of product for a trial period.
Denosumab injection (<i>Prolia</i>)	Postmenopausal osteoporosis in women	AMBER	Reviewed by PACEF and approved for use as an AMBER drug with shared care, appropriate for prescribing and administration in primary care following specialist initiation. (Peterborough & Leicester hospitals) Will remain as a RED hospital only drug where there is no shared care protocols in place (ULHT). MHRA recently released further advice on monitoring patients for the risk of hypocalcaemia and osteonecrosis of the jaw.
Estradiol 10mcg vaginal tablets (<i>Vagifem</i>)	Vaginal atrophy due to oestrogen deficiency in post menopausal women	GREEN	Added to the Formulary as an alternative to <i>Ortho-Gynest</i> pessaries which have been withdrawn.
Prochlorperazine 5mg/5ml Liquid	Nausea and vomiting	GREEN	The liquid formulation is now a lower cost option per dose than the buccal tablets so it has been approved for inclusion in the Lincolnshire Joint Formulary.
Ibuprofen gel 10% (<i>Fenbid</i>)	Musculoskeletal disorders	GREEN	The 10% strength of ibuprofen gel has been approved for inclusion in the Lincolnshire Joint Formulary. Where a 10% gel is required a low cost brand such as fenbid should be prescribed.

Further details can be found in PACE Bulletin volume 8 number 14 & 15

Lincolnshire Joint Formulary is available on-line www.lincolnshirejointformulary.nhs.uk